Meel, Michaël H <br/><br/>
Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  07 2020 
 - 3319-3332 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1557-3265 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-19-3538  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Benzocycloheptenes--pharmacology<br/>Biomarkers, Tumor<br/>Blood-Brain Barrier--drug effects<br/>Cell Line, Tumor<br/>Combined Modality Therapy<br/>Diffuse Intrinsic Pontine Glioma--drug therapy<br/>Disease Models, Animal<br/>Drug Synergism<br/>Epithelial-Mesenchymal Transition--drug effects<br/>Histone Deacetylase Inhibitors--pharmacology<br/>Histone Deacetylases--metabolism<br/>Humans<br/>Immunohistochemistry<br/>Mice<br/>Protein Kinase Inhibitors--pharmacology<br/>Proto-Oncogene Proteins--antagonists & inhibitors<br/>Receptor Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Triazoles--pharmacology<br/>Xenograft Model Antitumor Assays<br/>Axl Receptor Tyrosine Kinase